Type I interferons in anticancer immunity

Cited by (1,000)

Items 601–700 of 1,000

1. IFNAR1 Deficiency Impairs Immunostimulatory Properties of Neutrophils in Tumor-Draining Lymph Nodes
   Timon Hussain, Maksim Domnich, Sharareh Bordbari, Ekaterina Pylaeva, Elena Siakaeva, Ilona Spyra, Irem Ozel, Freya Droege, Anthony Squire, Stefan Lienenklaus et al. · 2022 · Frontiers in Immunology
2. Identification and Validation of an m7G-Related lncRNAs Signature for Prognostic Prediction and Immune Function Analysis in Endometrial Cancer
   Jiani Sun, Li Li, Hong Chen, Lei Gan, Xiaoqing Guo, Jing Sun · 2022 · Genes
3. RIG-I–like Receptor Regulation of Immune Cell Function and Therapeutic Implications
   Abigail Solstad, Octavia Hogaboam, Adriana Forero, Emily A. Hemann · 2022 · The Journal of Immunology
4. Mechano-bioconjugation Strategy Empowering Fusion Protein Therapeutics with Aggregation Resistance, Prolonged Circulation, and Enhanced Antitumor Efficacy
   Yajie Liu, Xilin Bai, Chengliang Lyu, Jing Fang, Fan Zhang, Wenhao Wu, Wei Wei, Wenbin Zhang · 2022 · Journal of the American Chemical Society
5. Immunological effects of radiopharmaceutical therapy
   Amanda G. Shea, Malick Bio Idrissou, Ana Isabel Torres, Tessa Chen, Reiner Hernandez, Zachary Scott Morris, Quaovi H. Sodji · 2024 · Frontiers in Nuclear Medicine
6. MiR-221 negatively regulates innate anti-viral response
   Hongqiang Du, Shuang Cui, Yunfei Li, Guang Yang, Peiyan Wang, Erol Fikrig, Fuping You · 2018 · PLoS ONE
7. Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production
   Yuanyuan Tong, Luyang Zhou, Limin Yang, Panpan Guo, Yanlan Cao, Frank Xiao-Feng Qin, Jianghuai Liu · 2018 · EBioMedicine
8. Exosome and Secretion: Action On?
   Ye Hu, Rui Zhang, Gang Chen · 2020 · Advances in experimental medicine and biology
9. Molecular characterisation of ILRUN, a novel inhibitor of proinflammatory and antimicrobial cytokines
   Rebecca L Ambrose, Aaron M. Brice, Alessandro T. Caputo, Marina R. Alexander, Leon Tribolet, Yu Chih Liu, Timothy E. Adams, Andrew G. D. Bean, Cameron R. Stewart · 2020 · Heliyon
10. Intratumoral antigen-presenting cell activation by a nanovesicle for the concurrent tertiary lymphoid structure de novo neogenesis
    Ran Cheng, Sucheng Li, Xianbin Ma, Wan‐Ru Zhuang, Yao Lei, Jiaqi He, Chao Lun Liang, Weidong Nie, Hai-Yan Xie · 2025 · Science Advances
11. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation
    Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Kim E. Ellison, Christopher J. Rivard, Tetsuya Mitsudomi, Fred R. Hirsch · 2017 · Journal of Thoracic Oncology
12. miR‐2909 regulates ISGylation system via STAT1 signalling through negative regulation of SOCS3 in prostate cancer
    Shiekh Gazalla Ayub, Deepak Kaul · 2017 · Andrology
13. COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death
    Tiziana Di Marco, Francesca Bianchi, Lucia Sfondrini, Katia Todoerti, Italia Bongarzone, Elisa Maffioli, Gabriella Tedeschi, Mara Mazzoni, Sonia Pagliardini, Sandra Pellegrini et al. · 2020 · Cancer Letters
14. Biomaterial-enabled therapeutic modulation of cGAS-STING signaling for enhancing antitumor immunity
    Yingqi Liu, Fei Yang, Xuan Wang, Bingbing Yang, Menghuan Li, Zhong Yuan Luo · 2023 · Molecular Therapy
15. TFR1-Mediated Iron Metabolism Orchestrates Tumor Ferroptosis and Immunity in Non-Small Cell Lung Cancer
    Zunqiao Wang, Xingkai Yao, Keping Wang, Bin Wang · 2023 · Journal of Environmental Pathology Toxicology and Oncology
16. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
    Carlos Luri‐Rey, Gabriel Gomis, Javier Glez‐Vaz, Almudena Manzanal, Ana Martinez Riaño, Maria Esperanza Rodriguez-Ruiz, Álvaro Teijeira, Ignacio Melero · 2023 · Immunological Reviews
17. Role of cellular metabolism in regulating type I interferon responses: Implications for tumour immunology and treatment
    Duale Ahmed, Edana Cassol · 2017 · Cancer Letters
18. Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response
    Fulvia Vascotto, Jutta Petschenka, Kerstin C. Walzer, Mathias Vormehr, Magdalena Brkic, Stefan Strobl, Roman Rösemann, Mustafa Diken, Sebastian Kreiter, Özlem Türeci et al. · 2019 · OncoImmunology
19. SOCS3 deletion in effector T cells confers an anti-tumorigenic role of IL-6 to the pro-tumorigenic cytokine
    Setsuko Mise‐Omata, Makoto Ando, Tanakorn Srirat, Kensuke Nakagawara, Taeko Hayakawa, Mana Iizuka-Koga, Hiroshi Nishimasu, Osamu Nureki, Minako Ito, Akihiko Yoshimura · 2023 · Cell Reports
20. Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2
    Candice Sakref, Alexis Saby, Céline Rodriguez, Maude Ardin, Lyvia Moudombi, Anne‐Claire Doffin, Élisa Gobbini, Aurélien Voissière, Laurie Besson, Léo Laoubi et al. · 2025 · Nature Communications
21. Oncolytic virus and immunogenic cell death in cancer therapy
    GuoXiu Cao, Chan Ding, Jun Dai, Xusheng Qiu · 2025 · Tumour Virus Research
22. Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies.
    Ariel Bulua Bourla, Dmitriy Zamarin · 2016 · PubMed
23. Cancer immune resistance: can theories converge?
    Rongze Olivia. Lu, Tolga Turan, Josue A. Samayoa, Francesco Maria Marincola · 2017 · Emerging Topics in Life Sciences
24. Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
    Marion G�rard, Camille Chatelain, Tiphaine Delaunay, Elvire Pons Tostivint, Jaafar Bennouna, Jean‐François Fonteneau · 2021 · Frontiers in Oncology
25. IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
    Katherine M. Audsley, Teagan Wagner, Clara Ta, Hannah V. Newnes, Anthony C. Buzzai, Samantha A. Barnes, Ben Wylie, Jesse D. Armitage, Tsuneyasu Kaisho, Anthony Bosco et al. · 2021 · Frontiers in Immunology
26. Oncolytic Activity of Wild-type Newcastle Disease Virus HK84 Against Hepatocellular Carcinoma Associated with Activation of Type I Interferon Signaling
    Liming Chen, Yongdong Niu, Jiating Sun, Hong Lin, Guoxi Liang, Min Xiao, Dongmei Shi, Jia Wang, Huachen Zhu, Yi Guan · 2021 · Journal of Clinical and Translational Hepatology
27. Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity
    Tao Zhang, Yu Wang, Qing Li, Liangyu Lin, Chunliang Xu, Yueqing Xue, Mingyuan Hu, Yufang Shi, Ying Wang · 2022 · Oncogene
28. Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials
    Minhan Jiang, Steven Fiering, Qi Shao · 2023 · Frontiers in Oncology
29. CD4+CCR8+ Tregs in ovarian cancer: a potential effector Tregs for immune regulation
    Shuna Liu, Ziqi Tao, Jianfang Lou, Rong Li, Xin Fu, Juan Xu, Ting Wang, Lei Zhang, Wenwen Shang, Yepeng Mao et al. · 2023 · Journal of Translational Medicine
30. Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses
    Diana Saleiro, Ewa M. Kościuczuk, Leonidas C. Platanias · 2016 · Cytokine & Growth Factor Reviews
31. IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better
    Giulia Marsili, Edvige Perrotti, Anna Lisa Remoli, Chiara Acchioni, Marco Sgarbanti, Angela Battistini · 2016 · Journal of Interferon & Cytokine Research
32. Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses
    Weng In Leong, Rachel Y. Ames, Jessica M. Haverkamp, Laura Torres, Janine Kline, Ashil Bans, Lauren Rocha, Marilena Gallotta, Cristiana Guiducci, Robert L. Coffman et al. · 2019 · Oncotarget
33. Immunometabolism of dendritic cells in health and disease
    Chuansheng Guo, Hongbo Chi · 2023 · Advances in immunology
34. DUSP4 modulates RIG-I- and STING-mediated IRF3-type I IFN response
    Huipeng Jiao, Sharmy J. James, Chin Wen Png, Chaoyu Cui, Heng Li, Liang Li, Wan Ni Chia, Nyo Min, Weiyun Li, Carla Claser et al. · 2024 · Cell Death and Differentiation
35. Manganese-Driven Plasmid Nanofibers Formed In Situ for Cancer Gene Delivery and Metalloimmunotherapy
    Jiexin Li, Ruiqi Yang, Chen Zhang, Jonathan F. Lovell, Yumiao Zhang · 2025 · Journal of the American Chemical Society
36. Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade
    Chia-Yang Hung, Elaine Y. Kang, Karol Jacek, Chunsong Yu, Xiaowei Zhang, Yicheng Zhu, Maryam Aftabizadeh, Robyn A. Wong, Behnam Badie, Piotr M. Swiderski et al. · 2025 · Neuro-Oncology
37. DNA methyltransferase inhibition promotes recruitment of myeloid-derived suppressor cells to the tumor microenvironment through induction of tumor cell-intrinsic interleukin-1
    Sofie Traynor, Mikkel G. Terp, Aaraby Nielsen, Per Guldberg, Mie K. Jakobsen, Pernille Gejl Pedersen, Odd Lilleng Gammelgaard, Christina Bøg Pedersen, Mathilde Pedersen, Sofie Rattenborg et al. · 2022 · Cancer Letters
38. RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer
    Jeffrey Patterson-Fortin, Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita Kuldeep Mehta, Jennifer L. Guerriero, Gerburg M. Wulf, Brian Matthew Wolpin, Ben Z. Stanger et al. · 2023 · Nature Communications · Retracted
39. Sending a Message: Use of mRNA Vaccines to Target the Tumor Immune Microenvironment
    Fabiola Ramirez, Angelica Zambrano, Robert Hennis, Nathan A. Holland, Rajkumar Lakshmanaswamy, Jessica Ann Chacon · 2023 · Vaccines
40. RNA Methyltransferase FTSJ3 Regulates the Type I Interferon Pathway to Promote Hepatocellular Carcinoma Immune Evasion
    Qiuyu Zhuang, Zhiguo Dai, Xuechun Xu, Shaoyi Bai, Yindan Zhang, Youshi Zheng, Xiaohua Xing, En Hu, Yingchao Wang, Wuhua Guo et al. · 2023 · Cancer Research
41. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer
    Yi Zhou, Huali Li, Yaxin Zhang, Enen Zhao, Chengmei Huang, Xingyan Pan, Feng Shu, Zhihao Liu, Na Tang, Fengtian Li et al. · 2024 · Cancer Letters
42. Virus nanotechnology for intratumoural immunotherapy
    Anthony O. Omole, Zhongchao Zhao, Sabrina Chang-Liao, Jessica Fernanda Affonso de Oliveira, Christine E. Boone, Lucas Sutorus, M. Sack, Judith A. Varner, Steven Fiering, Nicole F. Steinmetz · 2024 · Nature Reviews Bioengineering
43. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy
    Meng Michelle Xu, Yeong‐Shiau Pu, Ralph R. Weichselbaum, Yang‐Xin Fu · 2016 · Oncogene
44. Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity
    Saikat Manna, Sampa Maiti, Jingjing Shen, Wenjun Du, Aaron Palmer Esser-Kahn · 2020 · ACS Central Science
45. DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition
    Anita K. Bakrania, Bhavesh C. Variya, Lalaji V. Rathod, Snehal Sanjay Patel · 2017 · European Journal of Pharmaceutics and Biopharmaceutics
46. Targeting KDM4 family epigenetically triggers antitumour immunity via enhancing tumour‐intrinsic innate sensing and immunogenicity
    Mayu Sun, Xiaoyu Han, Jinyang Li, Jiali Zheng, Jingquan Li, Hui Wang, Xiaoguang Li · 2024 · Clinical and Translational Medicine
47. The importance of type I interferon in orchestrating the cytotoxic T-cell response to cancer
    Julia Busselaar, Merel Sijbranda, Jannie G. Borst · 2024 · Immunology Letters
48. The added value of type I interferons to cytotoxic treatments of cancer
    Laura Bracci, Antonella Sistigu, Enrico Proietti, Federica Moschella · 2017 · Cytokine & Growth Factor Reviews
49. The Transcription Factor IRF9 Promotes Colorectal Cancer via Modulating the IL-6/STAT3 Signaling Axis
    Bhesh Raj Sharma, Rajendra Karki, Balamurugan Sundaram, Yaqiu Wang, Peter Vogel, Thirumala‐Devi Kanneganti · 2022 · Cancers
50. Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy
    Xiangyuan Luo, Xiaoyu Ji, Meng Xie, Tongyue Zhang, Yijun Wang, Mengyu Sun, Wenjie Huang, Limin Xia · 2022 · Cancers
51. Diversification of circulating and tumor‐infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1−)‐pDC subset negatively correlated with clinical outcomes in melanoma patients
    Eleonora Sosa Cuevas, Nathalie Bendriss‐Vermare, Stéphane Mouret, Florence de Fraipont, Julie Charles, Jenny Valladeau‐Guilemond, Laurence Chaperot, Caroline Aspord · 2022 · Clinical & Translational Immunology
52. Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer
    Takashi Akiyoshi, Zhe Wang, Tomoko Kaneyasu, Osamu Gotoh, Norio Tanaka, Sayuri Amino, Noriko Yamamoto, Hiroshi Kawachi, Toshiki Mukai, Yukiharu Hiyoshi et al. · 2023 · JAMA Network Open
53. Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma
    Bing Zhu, Xinyan Wang, Takaya Shimura, Andrew C Huang, Nana Kong, Yujie Dai, Jianmin Fang, Peng Guo, Jie-Er Ying · 2023 · npj Precision Oncology
54. The role of immune checkpoint inhibition in triple negative breast cancer
    Kidist Tarekegn, Merve Keskinkılıç, Tyler J. Kristoff, Sean T. Evans, Kevin M. Kalinsky · 2023 · Expert Review of Anticancer Therapy
55. Viral infection and spread are inhibited by the polyubiquitination and downregulation of TRPV2 channel by the interferon-stimulated gene TRIM21
    Yu‐Yao Guo, Yue Gao, Yun-Lin Zhao, Chang Xie, Hu Gan, Xufeng Cheng, Li-Ping Yang, Junyan Hu, Hong‐Bing Shu, Bo Zhong et al. · 2024 · Cell Reports
56. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC
    Nikolaus John, Verena Schlintl, Teresa Sassmann, Joerg Lindenmann, Melanie Fediuk, Robert Wurm, Philipp Douschan, Martin Zacharias, Lipika Kalson, Florian Posch et al. · 2024 · Journal for ImmunoTherapy of Cancer
57. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon
    Kang-Jian Zhang, Xiaofei Yin, Yuanqin Yang, Huiling Li, Yanni Xu, Lie-Yang Chen, Xi-Jun Liu, Sujing Yuan, Xian-Long Fang, Jing Xiao et al. · 2016 · Clinical Cancer Research
58. Activation of viral defense signaling in cancer
    María González‐Cao, Niki Karachaliou, Mariacarmela Santarpía, Santiago Viteri, Andreas Meyerhans, Rafael Rosell · 2018 · Therapeutic Advances in Medical Oncology
59. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma
    Buyun Ma, Kan Chen, Pengyu Liu, Meng Li, Jiaye Liu, Kostandinos Sideras, Dave Sprengers, Katharina Biermann, Wenshi Wang, Jan N.M. IJzermans et al. · 2018 · Journal of Molecular Medicine
60. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials
    Gaber Plavc, Primož Strojan · 2020 · Radiology and Oncology
61. Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift
    Matilde Monti, Giorgia Ferrari, Valentina Grosso, Francesco Missale, Mattia Bugatti, Valeria Cancila, Stefania Zini, Agnese Segala, Luca La Via, Francesca Consoli et al. · 2024 · Frontiers in Immunology
62. A trinity STING-activating nanoparticle harnesses cancer cell STING machinery for enhanced immunotherapy
    Yanming Xia, Bo Shi, Keke Wang, Li‐Xin Hu, Qiran Wang, Shuxian Xu, Xiaohu Wang, Pengcheng Xu, Yuanbin She, Haitang Xie et al. · 2024 · Journal of Controlled Release
63. The role of type I interferon signaling in myeloid anti-tumor immunity
    Sofie Patrizia Meyer, Rebekka Bauer, Bernhard Brüne, Tobias Schmid · 2025 · Frontiers in Immunology
64. Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects
    Lijuan Lyu, Ming Yi, Jihua Chen, Jing Zhang, Xiaobin Ma, Xiaojun Zhang, Liang Zeng, Yan Xue, Haimei Wen, Yujiao Deng et al. · 2025 · Advanced Science
65. Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution
    Chunliang Liu, Xiang Wang, Erdong Liu, Yali Zong, Wenlong Yu, Youhai Jiang, Jianan Chen, Mingye Gu, Zhengyuan Meng, Jingfeng Li et al. · 2025 · Journal of Hematology & Oncology
66. Innate Immunity in Cancer Biology and Therapy
    Yuxia Zhang, Wenjing Xue, Caili Xu, Yanyang Nan, Shuang Mei, Dianwen Ju, Shaofei Wang, Xuyao Zhang · 2023 · International Journal of Molecular Sciences
67. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor
    Jia Yu, Fen Xiong, Yingruo Xu, Hanyan Xu, Xi Zhang, Hongchang Gao, Yuping Li · 2023 · International Immunopharmacology
68. Cellular fate of a plant virus immunotherapy candidate
    Anthony O. Omole, Jessica Fernanda Affonso de Oliveira, Lucas Sutorus, Sweta Karan, Zhongchao Zhao, Barry W. Neun, Edward Cedrone, Jeffrey D. Clogston, Jie Xu, Michael L. Sierk et al. · 2024 · Communications Biology
69. The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma
    Lin-ang Wang, Bo Yang, Wen Rao, Hualiang Xiao, Dong Wang, Jun Jiang · 2019 · OncoTargets and Therapy
70. Measles Vaccines Designed for Enhanced CD8+ T Cell Activation
    Elena Busch, Kristina Dorothea Kubon, J. Mayer, Gemma Pidelaserra-Martí, Jessica Albert, Birgit Hoyler, Johannes P.W. Heidbuechel, Kyle B. Stephenson, Brian Dennis Lichty, Wolfram Osen et al. · 2020 · Viruses
71. Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer
    Jing Cai, Wenfeng Liu, Chun-Wa Wong, Wenbo Zhu, Yuan Lin, Jun X. Hu, Wencang Xu, Jifu Zhang, Max Sander, Zhuo Wang et al. · 2020 · Oncogene
72. Dynamical Boolean Modeling of Immunogenic Cell Death
    Andrea Checcoli, Jonathan G. Pol, Aurélien Naldi, Vincent Noel, Emmanuel Barillot, Guido Kroemer, Denis Thieffry, Laurence Calzone, Gautier Stoll · 2020 · Frontiers in Physiology
73. Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer
    Reza Mehdizadeh, Seyed Peyman Shariatpanahi, Bahram Goliaei, Sanam Peyvandi, Curzio Rüegg · 2021 · Cancers
74. NLRP4 negatively regulates type I interferon response and influences the outcome in anti‐programmed cell death protein (PD)‐1/PD‐ligand 1 therapy
    Hui Wang, Liliang Xia, Chengcheng Yao, Hui Dong, Yi Yang, Chong Li, Wenxiang Ji, Ruiming Sun, Huangqi Duan, Wenli Mengzhou et al. · 2021 · Cancer Science
75. Red Light Phototherapy Using Light-Emitting Diodes Inhibits Melanoma Proliferation and Alters Tumor Microenvironments
    Evan Austin, Alisen Huang, Jennifer Y. Wang, Marc Cohen, Edward R. Heilman, Emanual Maverakis, Josef Michl, Jared R. Jagdeo · 2022 · Frontiers in Oncology
76. The dual role of type I interferons in bacterial infections: from immune defense to pathogenesis
    Mingjie Qiu, Jiayang Li, Wenqi Wu, Jianan Ren, Xiuwen Wu · 2025 · mBio
77. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia
    Michael M. Boyiadzis, Michael Bishop, Rafat Abonour, Kenneth Carl Anderson, Stephen Maxted Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen van Besien, Peter Leif Bergsagel et al. · 2016 · Journal for ImmunoTherapy of Cancer
78. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
    Dakota W. Goad, Christian Bressy, Molly C. Holbrook, Valery Z. Grdzelishvili · 2021 · Molecular Therapy — Oncolytics
79. A Biodegradable Antigen Nanocapsule Promotes Anti‐Tumor Immunity via the cGAS‐STING Pathway
    Xiangqian Jia, Hang Chen, Meng‐Ling Wu, Luyao Wang, Tiantian Li, Jing Ma, Xueqing Yi, Pengcheng Tan, Peiyuan Zheng, Juanjuan Du · 2023 · Advanced Functional Materials
80. Targeting the stimulator of interferon genes (STING) in breast cancer
    MA Ying-rui, Bai Bu-Fan, Liu Deng, Shi Rong, Qianmei Zhou · 2023 · Frontiers in Pharmacology
81. Immunogenic chemotherapy: great potential for improving response rates
    Xiaojun Huang, Qinghuan Ren, Leixiang Yang, Di Cui, Chenyang Ma, Yueliang Zheng, Junjie Wu · 2023 · Frontiers in Oncology
82. Salmonella immunotherapy engineered with highly efficient tumor antigen coating establishes antigen-specific CD8+ T cell immunity and increases in antitumor efficacy with type I interferon combination therapy
    Suyang Wang, Michelle Cheng, Chao‐Cheng Chen, Chia‐Yu Chang, Ya-Chea Tsai, Jr-Ming Yang, T.‐C. Wu, Chuan‐Hsiang Huang, Chien‐Fu Hung · 2023 · OncoImmunology
83. A promising target for breast cancer: B7-H3
    Ying Jiang, Jiayu Liu, Lingyan Chen, Zhiwen Qian, Yan Zhang · 2024 · BMC Cancer
84. PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
    Jonathan J. Hodgins, John Abou‐Hamad, Colin O’Dwyer, Ash Hagerman, Edward Yakubovich, Christiano Tanese de Souza, Marie Marotel, Ariel Buchler, Saleh Fadel, Maria M. Park et al. · 2024 · The Journal of Experimental Medicine
85. Local administration of mRNA encoding cytokine cocktail confers potent anti-tumor immunity
    Zhigang Li, Ling Hu, Yiping Wang, Qi Liu, Jun Liu, Haiyan Long, Qi Li, Liping Luo, Yucai Peng · 2024 · Frontiers in Immunology
86. Metabolic deficiencies underlie reduced plasmacytoid dendritic cell IFN-I production following viral infection
    Trever T. Greene, Yeara Jo, Carolina Chiale, Mónica Macal, Ziyan Fang, Fawziyah S. Khatri, Alicia L Codrington, Katelynn R. Kazane, Elizabeth Akbulut, Shobha Swaminathan et al. · 2025 · Nature Communications
87. An isoform of AIF1 involved in breast cancer
    Ferial Amira Slim, Geneviève Ouellette, Kaoutar Ennour‐Idrissi, Simon Jacob, Caroline Diorio, Francine Durocher · 2018 · Cancer Cell International
88. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications
    Kristian Michael Hargadon · 2021 · British Journal of Dermatology
89. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer – Current Aspects
    Holger Bronger · 2021 · Geburtshilfe und Frauenheilkunde
90. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes
    Zhihua Zou, Debin Yu, Mingzhi Zhao, Liwei Dong, Lu Hua Zhao, Mingwei Zou, Hongyu Liu, Mengying Zhang, Hetong Sun · 2016 · Drug Design Development and Therapy
91. Inhibition of O-GlcNAc transferase activates type I interferon-dependent antitumor immunity by bridging cGAS-STING pathway
    Jianwen Chen, Bao Lu Zhao, Hong Dong, Tianliang Li, Xiang Cheng, Wang Gong, Jing Wang, Junran Zhang, Gang Xin, Yanbao Yu et al. · 2024 · eLife
92. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction
    Xin Zhao, Bin Liu, William N. William, Kaloyan M. Tsanov, Yu-Jui Ho, Francisco M. Barriga, Raymond J. Lim, Maria Trifas, Azhar Khandekar, Yushen Du et al. · 2024 · Journal of Thoracic Oncology
93. Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
    Benjamin J. Wadowski, Raphael Bueno, Assunta De Rienzo · 2021 · Frontiers in Oncology
94. Targeting transgenic proteins to alpha granules for platelet-directed gene therapy
    Vanessa M.A. Woods, Lisette J. Latorre-Rey, Franziska Schenk, Marcel G. E. Rommel, Moritz Thomas, Ute Modlich · 2022 · Molecular Therapy — Nucleic Acids
95. cGAS-STING Pathway as the Target of Immunotherapy for Lung Cancer
    Hong Ge, Qinfu Dan, Yang Yang · 2022 · Current Cancer Drug Targets
96. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects
    Rong Huang, Yirong Wu, Zhengyun Zou · 2022 · Epigenomics
97. Cancer immunotherapy: T cells and neutrophils working together to attack cancers
    Ann Ager · 2023 · Cell
98. Myeloid MyD88 restricts CD8+ T cell response to radiation therapy in pancreatic cancer
    Terry R. Medler, Tiffany C. Blair, Alejandro F. Alice, Alexa K. Dowdell, Brian Piening, Marka R. Crittenden, Michael J. Gough · 2023 · Scientific Reports
99. Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer
    Connor H. O’Meara, Zuhayr Jafri, Levon Michael Khachigian · 2023 · International Journal of Molecular Sciences
100. Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR ‐T‐Cell Therapy
     Zhanna Zhang, Manqi Su, Panruo Jiang, Xiaoxia Wang, Xiangmin Tong, G. Wu · 2024 · Cancer Medicine